Moleculin Biotech, Inc. (MBRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US60855D4088
Moleculin Biotech, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -25.10 m USD |
| EBIT | -33.56 m USD |
| Net income | -33.56 m USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
More stocks
- Glucose Health, Inc. (GLUC)
- CISO Global, Inc. (CISO)
- AETERNUM HEALTH, INC. (AETN)
- ACCURAY INC (ARAY)
- INNOVATIVE DESIGNS INC (IVDN)
- GREENLITE VENTURES INC (GRNL)
- Upland Software, Inc. (UPLD)
- CalciMedica, Inc. (CALC)
- Vistagen Therapeutics, Inc. (VTGN)
- Summit Networks Inc. (SNTW)
- INTRUSION INC (INTZ)
- Reborn Coffee, Inc. (REBN)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.